Best Sermorelin Source: Scored Against a Pharmacy Standard

Any page that names a best sermorelin source without publishing its criteria first has written an advertisement. The order matters: weights, then evidence, then a number. Reverse it and the criteria get chosen to justify a conclusion that was already decided, which is what most of this category does.

So here are the weights before anything else. Testing scope on the batch document carries thirty points. Identity confirmation carries twenty. Batch traceability carries fifteen. Purity result and method carries ten, quantity verified against the label carries ten, domestic supply and written recourse carries ten, and price transparency carries five.

We link one supplier and take a commission on purchases made through it, as our affiliate disclosure page sets out. That is exactly why the heaviest criterion on this page is the one our own link scores worst on. A scoring system that happened to favour the thing we are paid for would not be worth publishing.

Testing scope beats purity because purity answers a narrower question than most buyers think. A purity figure tells you what share of the resolved material was the main peak. It does not tell you whether the powder carries bacterial endotoxin, and it does not tell you whether the vial is sterile. For a lyophilised powder that gets reconstituted, those are the assays that describe what happens next.

This is not a criterion we invented to look rigorous. FDA's stated reason for placing several peptides in Category 2 of its bulk substances list is the risk for immunogenicity, which the agency attributes to the potential for aggregation and peptide-related impurities. The framework is public on FDA's compounding pages. Whatever else a certificate reports, the question the agency itself raised for this class is a testing question.

Identity comes second at twenty points because a pure sample of the wrong molecule is a total failure rather than a partial one, and because identity is genuinely checkable by a reader. Traceability comes third at fifteen, because a certificate you cannot tie to the vial in your hand is a document about somebody else's batch.

Most source rankings in this market are graded on a curve against other research vendors, which is how a mediocre certificate ends up described as excellent. We anchor the scale somewhere else: to what a compounding pharmacy does when it prepares an injectable, because for this compound that comparison is available rather than hypothetical.

Sermorelin was an approved US medicine, sold as Geref by EMD Serono under NDA 019863 for the diagnostic product and NDA 020443 for the therapeutic version approved on 26 September 1997. Both are now discontinued, and Drugs@FDA carries the determination that the discontinuation was not for safety or effectiveness reasons. Because sermorelin acetate was a component of that approved product, section 503A permits a compounding pharmacy to work with it today.

So the top of this scale is not the best research vendor. It is a pharmacy fill with a label, a pharmacist and a record. No research source can score full marks against that anchor, and the scoring below reflects it rather than hiding it.

The evidence is one certificate. MZ Biolabs, Tucson, Arizona analysed lot 38-01260229 on 7 February 2026 and signed it on the thirteenth. Method: HPLC with ultraviolet and mass spectrometric detection, four detected peaks. Purity: 99.79%. Quantity: 11.31 mg measured against a 10 mg label. Named analyst on the document.

Identity scores full marks and we checked it ourselves rather than taking it on trust. The sequence printed on that certificate converts to YADAIFTNSYRKVLGQLSARKLLQDIMSR, twenty-nine residues with a C-terminal amide, which is canonical GHRH(1-29). The formula and mass the vendor states, C149H246N44O42S and 3357.9 g/mol, match PubChem CID 16132413 exactly.

Price transparency scores full marks too, for an unglamorous reason: the numbers are all published. $99.99 list, $72.00 site price, $36.00 with the code, quantity tiers at three, five and ten per cent off the list, and free shipping from $250. That is $3.60 per milligram on the label and $3.18 on the assayed 11.31 mg of that lot.

Eighteen of the twenty-one points lost are on the heaviest criterion. This lot's certificate reports purity and quantity, and carries no endotoxin test and no sterility test. Against a thirty-point criterion that expects both for injectable-format material, twelve points is a generous read rather than a harsh one, and it is awarded because the testing that is present is properly documented.

The remaining three points come off domestic supply and recourse. There is a domestic listing and a published seller policy, which is more than much of this market offers, but we have not tested a refund and we do not report on processes we have not seen. A score should reflect what has been verified rather than what is plausible.

Say all of this as a property of the batch rather than a verdict on the company. Lot 38-01260229 carries a certificate covering purity and quantity. A later lot could carry a wider panel, and if it does, the score moves. The check that survives any scoring system is opening the document attached to the lot number on your own vial and reading the assay list at the top. Our supplier checklist works through that step by step.

Three things sit outside this scale entirely, and no certificate can supply them. Nobody assesses whether the compound suits you. Nothing on the vial is an approved label with indications and contraindications. And there is no adverse event reporting route, because the material is not being supplied as a medicine.

The evidence question sits outside it as well, and it applies to every source equally. The approved indications were paediatric growth hormone deficiency and pituitary diagnostics. PubMed holds 332 papers mentioning sermorelin, three with it in the title, and zero pairing it with anti-aging. ClinicalTrials.gov registers no studies naming the compound. Choosing a better-documented vendor does not change any of that, and no source ranking should imply otherwise.

There is also a trap specific to this compound worth naming: searching trial registries returns dozens of studies that never name it, because they are GHRH, tesamorelin and octreotide work. Sermorelin is GHRH(1-29), so parts of the GHRH literature are genuinely relevant, but a GHRH trial is not a sermorelin trial and a source that cites one as though it were has told you something about its standards.

Seventy-nine out of a hundred, with the deductions itemised above. That is a reasonable score for a research listing and a poor one against the pharmacy anchor, and both readings are correct at the same time. It is not a recommendation, an endorsement, or a claim that this is the best source available anywhere, because we have not scored every seller in the market and would not pretend to.

What it is, is a method you can run yourself on any listing you find. Publish the weights, gather the certificate, check identity against the reference data, and refuse to award points for assays that are not on the document. If a competing source scores higher on that method, that is the correct conclusion and this page will not argue with it.

And if the deduction on testing scope is the part that matters most to you, the answer to it is not a different vendor. It is the other column entirely, which for this compound is genuinely open. Our guide to how to get a sermorelin prescription explains what that route asks and what it delivers.